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     We read with interest the article written by Božić et al [1]. More than 6 decades ago the 
aminoacid dimethylcysteine (penicillamine) was introduced into clinical medicine as a 
chelating agent [2] and the time is now ripe to review what is known of the chemistry, 
pharmacology and therapeutic action of this compound. D-penicillamine (D-PA) was first 
recognized as a potential benefit for neonatal hyperbilirubinemia. During this time there was 
a remarkably low incidence of retinopathy of prematurity in the infants treated with D-PA 
[3]. Later, our studies were replicated in other institutes in Hungary, Poland,  
U.S. A., India and Mexico [4-15]. It is important to note that there was no intolerance or 
short- or long-term toxicity of the medication, in spite of the fact that in the newborn period 
D-PA was used 10-20 times higher doses than those in adult. Furthermore, the aim of our 
recent article [16] was to demonstrate a new concept in the etiology of bilirubin-induced 
neurologic dysfunction (BIND) and highlight the role of D-PA. Unconjugated bilirubin has a 
special affinity for the globus pallidus, the hippocampus, and the subthalamic nucleus (basal 
ganglia). The copper metabolism in Wilson's disease and in newborn infants is strikingly 
similar. Both have large quantities of copper in the liver which is contrasted by an unusually 
low ceruloplasmin level in the blood. In strictly biological terms, at least 3 loci exist where 
UCB and copper can be "fusioned" in the neonatal period: (1) during hemolysis high UCB 
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and copper level can be developed in the blood; (2) one albumin can bind one Cu++ in the 
primary binding site. At higher concentration of copper (if possible under certain conditions), 
loosely bound atoms, and can be very easily taken out by UCB. The bile pigment itself can 
displace loosely bound copper ions, which are electrostatically attached due to high negative 
charge on the surface of albumin; (3) in the basal ganglia. Beside copper mobilization D-PA 
may play an important role in maintaining the sulphhydryl-disulphide equilibrium, thus, 
stabilizing the oxidation-reduction potential in the cell [17]. We hope that our concept will 
help answer the unsolved questions and concerns ocurred in the etiology and 
pathomechanisms of BIND and other neurodegenerative/neurodevelopmental disorders 
(NDs). The beneficial neuropharmacological actions of metal-targeted (chelating) agents 
most likely arise from local metal redistribution rather than from massive metal removal. The 
chelation therapy for non-metal overload indications continues to be investigated. Our present 
letter address the medical necessity of the use of a chelating agent (D-PA) in the prevention 
or treatment of neonatal brain injuries [18]. In addition copper dyshomeostasis and oxidative 
stress have also been concerned in NDs such as autism spectrum disorder (ASD) [19,20].   
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